UPLOAD Filing
ANAVEX LIFE SCIENCES CORP.
Date: July 21, 2025 · CIK: 0001314052 · Accession: 0000000000-25-007655
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288661
Letter
Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed July 14, 2025 File No. 333-288661 Dear Christopher Missling:
July 21, 2025
Christopher Missling Chief Executive Officer Anavex Life Sciences Corp. 630 5th Avenue, 20th Floor New York, NY 10111
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Erin L. Fogarty, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 21, 2025 Christopher Missling Chief Executive Officer Anavex Life Sciences Corp. 630 5th Avenue, 20th Floor New York, NY 10111 Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed July 14, 2025 File No. 333-288661 Dear Christopher Missling: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Erin L. Fogarty, Esq. </TEXT> </DOCUMENT>